目的:本研究的目的是识别和验证可用于远程眼科门户的基于智能手机的视敏度(VA)应用程序。
方法:该研究分三个阶段进行:调查SmartOptometry应用程序是否易于下载,理解和测试(第一阶段),使用四种工具,即COMPlog,以随机测试顺序测量的VA的临床比较斯内伦近视减少,PeekAcuity(距离VA)和SmartOptometry(近VA)(II期)以及通过再次测量VA(III期)对这4种工具的可重复性研究。该研究招募了我们研究所的员工,并遵守严格的COVID-19检测方案。
结果:第一阶段调查(n=40)显示90%的参与者使用Android手机,60%的人报告说指示很清楚,所有用户都能够使用SmartOptometry应用程序进行自我评估。第二阶段(n=68)显示,窥视能力与COMPlogVA相当(P=0.31),然而,SmartOptometry与ReducedSnellen近视力测试在统计学上显着不同(在2logMAR线内),特别是年轻(n=44,P=0.004)和正视(n=16,P=0.04)参与者。发现所有4项测试在第三阶段(n=10)均可重复,重复性系数≤0.14。
结论:基于智能手机的应用程序易于下载,可用于检查患者的距离和近视敏度。解释结果时应考虑年龄和屈光不正的影响。需要对实时患者进行进一步研究,以确定潜在的益处和需要解决的挑战。
OBJECTIVE: The objective of this study was to identify and validate smartphone-based visual acuity (VA) apps that can be used in a teleophthalmology portal.
METHODS: The study was conducted in three phases: A survey to investigate if the SmartOptometry App was easy to download, understand and test (phase I), an in-clinic comparison of VA measured in a random testing order with four tools namely COMPlog, Reduced Snellen near vision, Peek Acuity (Distance VA) and SmartOptometry (Near VA) (phase II) and a repeatability study on these 4 tools by measuring VA again (phase III). The study recruited the employees of our institute and adhered to the strict COVID-19 protocols of testing.
RESULTS: Phase I Survey (n = 40) showed 90% of participants used android phones, 60% reported that instructions were clear, and all users were able to self-assess their near VA with SmartOptometry App. Phase II (n = 68) revealed that Peek Acuity was comparable to COMPlog VA (P = 0.31), however SmartOptometry was statistically significantly different (within 2 log MAR lines) from Reduced Snellen near vision test, particularly for young (n = 44, P = 0.004) and emmetropic (n = 16, P = 0.04) participants. All the 4 tests were found to be repeatable in phase III (n = 10) with a coefficient of repeatability ≤0.14.
CONCLUSIONS: Smartphone-based apps were easy to download and can be used for checking patient\'s distance and near visual acuity. An effect of age and refractive error should be considered when interpreting the results. Further studies with real-time patients are required to identify potential benefits and challenges to solve.